相似文献
1
The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
Vaccine. 2009 Jun 2;27(27):3544-52. doi: 10.1016/j.vaccine.2009.03.069. Epub 2009 Apr 14.
2
Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Eur J Pharm Biopharm. 2015 Jun;93:149-64. doi: 10.1016/j.ejpb.2015.03.024. Epub 2015 Mar 26.
3
A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen.
Vaccine. 2013 Mar 1;31(11):1480-9. doi: 10.1016/j.vaccine.2013.01.012. Epub 2013 Jan 23.
4
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
J Immunol. 2003 Jun 1;170(11):5636-43. doi: 10.4049/jimmunol.170.11.5636.
5
Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
Infect Immun. 2007 Aug;75(8):4020-9. doi: 10.1128/IAI.00070-07. Epub 2007 May 14.
6
Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
Vaccine. 2015 Feb 18;33(8):1008-16. doi: 10.1016/j.vaccine.2015.01.013. Epub 2015 Jan 14.
7
Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Pharm Res. 2006 Jun;23(6):1217-26. doi: 10.1007/s11095-006-0206-9. Epub 2006 May 25.
8
A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
J Immunol. 2016 Jan 1;196(1):284-97. doi: 10.4049/jimmunol.1501903. Epub 2015 Nov 25.
9
Needle-free skin patch vaccination method for anthrax.
Infect Immun. 2004 Feb;72(2):1181-3. doi: 10.1128/IAI.72.2.1181-1183.2004.
10
Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination.
Vaccine. 2015 Jul 17;33(31):3609-13. doi: 10.1016/j.vaccine.2015.06.037. Epub 2015 Jun 15.
引用本文的文献
1
Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.
Clin Exp Vaccine Res. 2025 Jul;14(3):246-260. doi: 10.7774/cevr.2025.14.e23. Epub 2025 Apr 15.
2
DNA Methylation Negatively Regulates Gene Expression of Key Cytokines Secreted by BMMCs Recognizing FMDV-VLPs.
Int J Mol Sci. 2024 Oct 9;25(19):10849. doi: 10.3390/ijms251910849.
3
Development of a broadly active influenza intranasal vaccine adjuvanted with self-assembled particles composed of mastoparan-7 and CpG.
Front Immunol. 2023 Mar 24;14:1103765. doi: 10.3389/fimmu.2023.1103765. eCollection 2023.
4
Delivery of small molecule mast cell activators for West Nile Virus vaccination using acetalated dextran microparticles.
Int J Pharm. 2023 Mar 5;634:122658. doi: 10.1016/j.ijpharm.2023.122658. Epub 2023 Jan 30.
5
Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.
Cells. 2020 Dec 18;9(12):2713. doi: 10.3390/cells9122713.
6
Mast Cell Functions Linking Innate Sensing to Adaptive Immunity.
Cells. 2020 Nov 25;9(12):2538. doi: 10.3390/cells9122538.
7
Novel mucosal adjuvant, mastoparan-7, improves cocaine vaccine efficacy.
NPJ Vaccines. 2020 Feb 5;5(1):12. doi: 10.1038/s41541-020-0161-1. eCollection 2020.
8
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
J Virol. 2019 Jun 28;93(14). doi: 10.1128/JVI.00475-19. Print 2019 Jul 15.
9
Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant.
Pharmaceutics. 2019 Feb 9;11(2):72. doi: 10.3390/pharmaceutics11020072.
10
Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.
J Immunol. 2019 Feb 15;202(4):1229-1238. doi: 10.4049/jimmunol.1801227. Epub 2019 Jan 16.
本文引用的文献
1
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer.
J Clin Oncol. 2008 Sep 20;26(27):4418-25. doi: 10.1200/JCO.2008.16.6462.
2
Anaphylaxis following quadrivalent human papillomavirus vaccination.
CMAJ. 2008 Sep 9;179(6):525-33. doi: 10.1503/cmaj.080916. Epub 2008 Sep 1.
3
B cell chemoattractant CXCL13 is preferentially expressed by human Th17 cell clones.
J Immunol. 2008 Jul 1;181(1):186-9. doi: 10.4049/jimmunol.181.1.186.
4
Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination.
Vaccine. 2008 May 23;26(22):2700-5. doi: 10.1016/j.vaccine.2008.03.016. Epub 2008 Mar 31.
5
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
PLoS One. 2008 Apr 23;3(4):e1993. doi: 10.1371/journal.pone.0001993.
6
Mast cell activators: a new class of highly effective vaccine adjuvants.
Nat Med. 2008 May;14(5):536-41. doi: 10.1038/nm1757. Epub 2008 Apr 20.
7
A sheep in wolf's clothes: can neutrophils direct the immune response?
Vet J. 2009 May;180(2):169-77. doi: 10.1016/j.tvjl.2007.12.030. Epub 2008 Mar 4.
8
Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
Vaccine. 2008 Jan 24;26(4):552-61. doi: 10.1016/j.vaccine.2007.11.054. Epub 2007 Dec 7.
9
Th17 cells: effector T cells with inflammatory properties.
Semin Immunol. 2007 Dec;19(6):362-71. doi: 10.1016/j.smim.2007.10.007. Epub 2007 Nov 26.
10
How do adjuvants work? Important considerations for new generation adjuvants.
Immunity. 2007 Nov;27(5):687-90. doi: 10.1016/j.immuni.2007.11.003.
Zotero 插件